Randomized phase III study of nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung.

Trial Profile

Randomized phase III study of nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cisplatin; Nedaplatin
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2015 Results published in the Lancet Oncology
    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top